Gossamer Bio Inc. (GOSS)
NASDAQ: GOSSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
GOSS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $65.57M
- EPS (TTM)
- -$42.41
- Dividend yield
- None
- 52-week range
- 8.29 – 309.60
- Day range
- 10.65 – 11.60
- Volume / Avg
- 191.36K / 243.40K
- Beta
- —
- Shares outstanding
- 6.12M
52-week range
GOSS stock today
Shares of Gossamer Bio (GOSS) finished lower on Nov 20 at $10.72, a drop of 4.54% or $0.51 per share, versus the S&P 500's 3.70% decline. At this level, GOSS sits near the bottom of its 52-week range of $8.29 to $309.60: 96.5% below the high, set on Dec 15, 2025 and 29.3% above the low. GOSS is down 95.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 95.6%.
Gossamer Bio has posted a net loss over the last twelve months (EPS of -$42.41), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Gossamer Bio
Company profileGossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Faheem Hasnain
- Headquarters
- San Diego, CA
- Employees
- 161
- IPO year
- 2019
- Website
- gossamerbio.com
Financial highlights
Full financialsIn fiscal 2025, Gossamer Bio generated $48.5 million in revenue, down 57.7% from fiscal 2024, the first decline in the 9 years shown. Gossamer Bio reported a net loss of $170.4 million, compared with a loss of $56.5 million a year earlier. Operating margin was -352.2%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $48.47M | $114.70M | $0 | $0 | — |
| Growth | -57.74% | — | — | — | — |
| Net income | $-170.37M | $-56.53M | $-179.82M | $-229.38M | $-234.00M |
| EPS (diluted) | $-0.75 | $-0.25 | $-1.18 | $-2.71 | $-3.13 |
Analyst forecast
ForecastConsensus (7 analysts)
buy
Avg. price target
$82.48+669.40%
- Strong buy 1
- Buy 2
- Hold 3
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 10, 2026
- EPS actual vs est.
- $-1.19 vs $-5.55
- Surprise
- +78.56%
GOSS news
All GOSS news- Gossamer Bio Announces Third Quarter 2026 Financial Results and Provides Business UpdateBusiness Wire
- TG Therapeutics (TGTX) Beats Q3 Earnings and Revenue EstimatesNasdaqTGTX, GOSS
- Gossamer Bio Stockholders Approve Share Issuance Proposal Under Securities Purchase Agreement Dated August 20, 2026NasdaqGOSS, HEI.A
Gossamer Bio peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PMVPPMV Pharmaceuticals Inc. | 0.876 | -33.13% | $66.17M | vs GOSS |
| PLYXPolaryx Therapeutics Inc. | 1.33 | -11.92% | $66.30M | vs GOSS |
| FBIOFortress Biotech Inc. | 1.90 | +7.34% | $64.11M | vs GOSS |
| MNOVMedicinova Inc | 1.31 | +3.15% | $67.11M | vs GOSS |
| CINGCingulate Inc. | 4.51 | -14.26% | $67.48M | vs GOSS |
| MAIAMAIA Biotechnology Inc. | 1.11 | -2.63% | $68.54M | vs GOSS |
| VTVTvTv Therapeutics Inc. Class A | 15.51 | -5.20% | $62.22M | vs GOSS |
| COYACoya Therapeutics Inc. | 2.95 | -1.01% | $69.20M | vs GOSS |
Indexes, lists and sector
Gossamer Bio stock FAQ
What is Gossamer Bio's stock price today?
GOSS last traded at $10.72 as of Nov 20, 4:00 PM EST, down 4.54% on the day. Prices are delayed at least 15 minutes.
Does Gossamer Bio pay a dividend?
No. Gossamer Bio does not currently pay a regular cash dividend.
Who is Gossamer Bio's CEO?
Mr. Faheem Hasnain is the chief executive officer of Gossamer Bio Inc., which has about 161 employees.
Has GOSS ever split its stock?
Yes. The most recent GOSS stock split was a 1-for-80 split on Sep 11, 2026.
What is the GOSS 52-week high?
The 52-week high for GOSS is $309.60 and the 52-week low is $8.29. The stock is currently 96.5% below its high.